Gnosis unveiled a new clinical study on Mythocondro, which investigated the efficacy of Non-Animal Chondroitin Sulfate in the treatment of moderate knee osteoarthritis. The study concluded with significant positive results achieved for all endpoints tested, and will be shortly published, according to the company.
 
The randomized, double-blind, placebo-controlled study was carried out in participation with the University of Pavia (Italy), on 60 individuals (male and female), supplemented with low dosage of Mythocondro (600 mg/day) for 12 weeks, with endpoints set at T0, T1 (4 weeks) and at T2 (12 weeks).
 
Primary endpoints for the evaluation included: 

• Pain intensity measured both in motion and at rest, using the Visual Analogue Scale (VAS)
• Assessment of knee function by WOMAC (Western Ontario and McMaster Universities Arthritis) Index.
• Assessment of Tegner Lysholm Knee Scoring (that measures how much knee pain has affected the ability to manage in everyday life).

Secondary endpoints evaluated included:

• Health-related quality of life, recorded by the ShortForm36 (SF-36).
• Inflammation markers in plasma: C-reactive protein (CRP), erythrocyte sedimentation rate (VES)

All endpoint results show a statistically significant modification of the parameters with impressive results related to the decrease in the Womac Score and the Lysholm Knee Scoring Scale.
 
Gnosis is investigating Mythocondro’s short-term effects with the SCOPE study (non-animal CS in Obesity and Physical Exercise) to demonstrate the antioxidant, anti-inflammatory, and chondroprotective properties at low dose.